Morgan Stanley Lifts Price Target on Regeneron Pharmaceuticals to $941 From $914, Keeps Overweight Rating
Morgan Stanley Lifts Price Target on Regeneron Pharmaceuticals to $941 From $914, Keeps Overweight Rating
摩根士丹利將Regeneron Pharmicals的目標股價從914美元上調至941美元,維持增持評級
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊